Acetyl-L-Carnitine (ALCAR), graded Moderate-evidence on Magellan — depression trials are highly heterogeneous and mostly older, and a Cochrane review found no cognitive benefit in healthy people. Not proven for general anti-aging. Studied dose: 1.5–3 g/day in trials. Magellan links 26 peer-reviewed citations for Acetyl-L-Carnitine (ALCAR).
Source: Cochrane Database Syst Rev 2003, PMID 12804452 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high
Acetyl-L-carnitine (ALCAR) is the acetylated ester of the amino-acid derivative L-carnitine, a compound the body makes from lysine and methionine and also obtains from meat and dairy. Carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, the reaction that generates cellular energy, while ALCAR additionally supplies acetyl groups used in acetylcholine and neurotransmitter synthesis. Because it crosses the blood-brain barrier more readily than L-carnitine, ALCAR has a comparatively prominent role in the nervous system.
Randomized trials and meta-analyses report modest benefits on cognition in mild cognitive impairment and mild Alzheimer's disease, on depressive symptoms — two meta-analyses (2018 and 2026) find efficacy comparable to antidepressants with fewer side effects, strongest in older adults — and on physical and mental fatigue in very old adults, whereas a Cochrane review found no clear cognitive benefit in healthy people and the evidence in diabetic neuropathy remains uncertain. Proposed mechanisms center on mitochondrial energy metabolism, acetyl donation for neurotransmitter synthesis, and correction of the low acetyl-L-carnitine levels seen in depression. Caveats: the depression trials are highly heterogeneous and many are older, large modern trials are absent, and for general anti-aging claims the human evidence is indirect. This evidence describes the acetyl-L-carnitine compound and related carnitine research itself, not this specific commercial product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“There is evidence for benefit of acetyl-L-carnitine on clinical global impression”
“ALCAR treatment delays degenerative disorders with improvement in memory and cognitive processes”
“A pooled analysis of two randomized placebo-controlled trials showed acetyl-L-carnitine alleviated symptoms, particularly pain, and improved nerve fiber regeneration in established diabetic neuropathy.”
“ALC reduced pain more than placebo, measured on a 0- to 100-mm VAS (MD -9.16, 95% CI -16.76 to -1.57; three studies; 540 participants; P = 0.02; I² = 56%; random-effects; very low-certainty evidence; a higher score indicating more pain).”
“The current evidence suggests that ALC has a moderate effect in reducing pain measured on VAS in PNP patients with acceptable safety.”
“Fibromyalgia (FM) is characterised by a form of debilitating pain that is unresponsive to standard analgesics.”
Research describes the active mechanism and is not a claim about this specific product.
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Across meta-analyses and randomized trials, creatine monohydrate combined with…
In humans, randomized trials and meta-analyses most consistently show that astaxanthin…
Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…
Yes — its active compound is linked to 26 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.